{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-000419","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2024-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.106792+00:00","generated_at":"2026-06-07T04:35:17.420346+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vistagen receives EPO notice of intention to grant AV-101 patent for neuropathic pain","bullets":["European Patent Office issued Notice of Intention to Grant patent for AV-101 to treat neuropathic pain.","Patent will not expire until at least 2034; adds to global AV-101 portfolio.","Preclinical data show AV-101 similar efficacy to gabapentin and pregabalin with better side effect profile.","Phase 1 data demonstrate AV-101 well-tolerated with no meaningful difference vs placebo.","Vistagen plans to seek strategic collaborations to advance AV-101 development."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-000419","json":"https://secwatch.observer/filing/0001437749-24-000419.json","markdown":"https://secwatch.observer/filing/0001437749-24-000419.md","text":"https://secwatch.observer/filing/0001437749-24-000419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924000419/0001437749-24-000419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924000419/vtgn20240103_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:35:17.420346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}